Drug intelligence / Profile preview

NYH100P

Development stage: Phase 1
Lead developer: Haim Bio
Modality: Small Molecules
Administration: Oral

Overview

NYH100P is an orally bioavailable small molecule inhibitor of mitochondrial complex I, under development for the treatment of advanced solid tumors. It is being investigated both as a monotherapy and in combination with the ALDH inhibitor NYH817G (the combination is also referred to as Starvanip or NYH817100). The mechanism of action involves inhibition of mitochondrial complex I, leading to disruption of cancer cell energy metabolism, induction of apoptosis and autophagy, and potential inhibition of cancer cell growth. The drug is being developed by Haim Bio, with clinical trials targeting patients who have failed standard therapies for advanced solid tumors[2][4][7].

Other names: gossypol

Targets

ND1 (Mitochondrial electron transport chain complex I)

Beyond the preview

Go deeper on NYH100P.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NYH100P.

Explore the full profile